Clearside Biomedical

Clearside Biomedical Working Capital

Delisted

The Working Capital of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 16.48 M USD. In the previous year, Working Capital was 23.31 M USD — a change of -29.30% (lower).

Working Capital

16.48 MUSD

YoY

-29.30%

Last updated:

Working Capital of Clearside Biomedical is 2024 16.48 M USD. Working Capital of Clearside Biomedical was 2023 23.31 M USD. It decreases by -29.30% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Working Capital of Clearside Biomedical is 16.48 M USD in 2024.

Working Capital of Clearside Biomedical changed from 23.31 M USD to 16.48 M USD, representing a -29.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical